Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Am J Emerg Med. 2014 Jul 30;32(10):1195–1199. doi: 10.1016/j.ajem.2014.07.015

Table 4.

Rates of AAD among patients who received the classes of antibiotics in the ED

Antibiotic Number treated (%) Percentage with AAD (95% CI)
Cephalosporin 91 (36.8) 19.8 (11.4–28.1)
  Cephalosporin alone 47 (19.0) 14.9 (4.3–25.5)
  Cephalosporin + other 44 (17.8) 25.0 (11.7–38.3)
Bactrima 40 (16.2) 15.0 (3.4–26.6)
Vancomycinb 42 (17.0) 21.4 (8.5–34.4)
Clindamycin 50 (20.2) 30.0 (16.8–43.2)
  Clindamycin alone 34 (13.8) 26.5 (10.9–42.1)
  Clindamycin + other 16 (6.5) 37.5 (10.9–64.1)
Macrolide 21 (8.5) 19.0 (0.7–37.4)
  Macrolide alone 13 (5.3) 7.7 (0.0–24.5)
  Macrolide + other 8 (3.2) 37.5 (0.0–80.7)
All penicillinsc 46 (18.6) 19.6 (7.7–31.5)
Penicillin 20 (8.1) 25.0 (4.2–45.8)
  Penicillin alone 16 (6.5) 18.8 (0.0–40.2)
  Penicillin + other 4 (1.6) 50.0 (0.0–100)
Penicillin/I 26 (10.5) 15.4 (0.5–30.3)
  Penicillin/I alone 19 (7.7) 21.1 (0.8–41.2)
  Penicillin/I + other 7 (2.8) 0.0
Quinolone 29 (11.7) 6.9 (0.0–16.7)
  Quinolone alone 21 (8.5) 4.8 (0.0–14.7)
  Quinolone + other 8 (3.2) 12.5 (0.0–42.1)
Doxycycline + otherd 12 (8.5) 8.3 (0.0–26.7)

Quinolone = fluoroquinolones, penicillin/I= penicillin inhibitor combination antibiotic.

a

No difference when used as monotherapy or in combination.

b

Used only in combination with other antibiotics.

c

Combining the penicillin and PCN Combo groups.

d

All AAD in combination therapy group; 4 patients in monotherapy did not develop AAD.